Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Randomized, Adaptive, Two-Arm, Multicenter Trial to Evaluate Pharmacokinetics And Pharmacodynamics of Two Doses of Oseltamivir (Tamiflu®) in The Treatment Of Influenza in Immunocompromised Children Less Than 13 Years Of Age, With Confirmed Influenza Infection

NCT01715909 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01715909
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01715909 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Randomized, Adaptive, Two-Arm, Multicenter Trial to Evaluate Pharmacokinetics And Pharmacodynamics of Two Doses of Oseltamivir (Tamiflu®) in The Treatment Of Influenza in Immunocompromised Children Less Than 13 Years Of Age, With Confirmed Influenza Infection
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1
Overall status
Completed
Start date
January 22, 2014
Completion date
June 17, 2018
Enrollment
20 (estimated)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

influenza